Experimental drug improves psychosis in Parkinson's disease

10/31/2013 | HealthDay News

Data on 199 Parkinson's patients with disease-related psychosis showed those who took Acadia Pharmaceuticals' experimental drug pimavanserin attained significant improvements in psychotic symptoms at 43 days compared with the placebo arm. "Pimavanserin is not yet licensed, but could potentially offer a change in the treatment of these distressing and impactful symptoms," lead researcher Dr. Clive Ballard stated in The Lancet.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY